ENOS phosphorylation in health and disease

Biochimie

Volumn 92, Issue 9, 2010, Pages 1186-1198

  Kolluru, Gopi Krishna ^a   Siamwala, Jamila H ^a   Chatterjee, Suvro ^a  

^a ANNA UNIVERSITY   (India)

Author keywords

ENOS; Nitric oxide; Serine phosphorylation

Indexed keywords

BRADYKININ; CALCIUM; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; SERINE; THREONINE; TYROSINE; VASCULOTROPIN;

AGING; ALZHEIMER DISEASE; CELLULAR DISTRIBUTION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ERECTILE DYSFUNCTION; GENE EXPRESSION; HEART INFARCTION; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPOXIA; LIVER CIRRHOSIS; LIVER ISCHEMIA; MYRISTYLATION; NITROSYLATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PALMITOYLATION; PORTAL HYPERTENSION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; SUBARACHNOID HEMORRHAGE;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; SERINE;

EID: 77955846453     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.03.020     Document Type: Review

References (237)

1. Fleming I., Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284:1-12.
2. Panza J.A., Garcia C.E., Kilcoyne C.M., Quyyumi A.A., Cannon R.O. Evidence that endothelial dysfunction in patients with hypercholesterolemia is not due to increased extracellular nitric oxide breakdown by superoxide anions. 3rd Circul. 1995, 91:1732-1738.
3. Cooke J.P., Losordo D.W. Nitric oxide and angiogenesis. Circulation 2002, 105:2133-2135.
4. Naseem K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspect. Med. 2005, 26:33-65.
5. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:4651-4655.
6. Lefer D.J., Jones S.P., Girod W.G., et al. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am. J. Physiol. 1999, 276:1943-1950.
7. Jones S.P., Girod W.G., Palazzo A.J., Granger D.N., Grisham M.B., Jourd'Heuil D., et al. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am. J. Physiol. 1999, 276:1567-1573.
8. Heeringa P., van Goor H., Itoh-Lindstrom Y., Maeda N., Falk R.J., Assmann K.J., et al. Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. Am. J. Pathol. 2000, 156:879-888.
9. Malhotra V., Orci L., Glick B.S., Block M.R., Rothman J.E. Role of an N-ethylmaleimide-sensitive transport component in promoting fusion of transport vesicles with cisternae of the Golgi stack. Cell 1988, 54:221-227.
10. Tai S.C., Robb G.B., Marsden P.A. Arterioscler. Thromb. Vasc. Biol. 2004, 24:405-412.
11. Fulton D., Fontana J., Sowa G., Gratton J.P., Lin M., Li K.X., Michell B., Kemp B.E., Rodman D., Sessa W.C. Localization of endothelial nitric-oxide synthase phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane defines the existence of two pools of active enzyme. J. Biol. Chem. 2002, 277:4277-4284.
12. Michel T., Feron O. Nitric oxide synthases: which, where, how, and why?. J. Clin. Invest. 1997, 100:2146-2152.
13. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001, 357:593-615.
14. Nathan C., Xie Q.-W. Nitric oxide synthase: roles, tolls and controls. Cell 1994, 78:915-918.
15. Papapetropoulos A., Rudic R.D., Sessa W.C. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc. Res. 1999, 43:509-520.
16. Wang Y., Marsden P.A. Nitric oxide synthases: gene structure and regulation. Adv. Pharmacol. 1995, 34:71-90.
17. Forstermann U., Boissel J.P., Kleinert H. Expressional control of the " constitutive" isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 1998, 12:773-790.
18. Nathan C., Xie Q.W. Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 1994, 269:3725-3728.
19. Papapetropoulos A., García-Cardeña G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 1997, 100:3131-3139.
20. Simoncini T., Varone G., Fornari L., Mannella P., Luisi M., Labrie F., Genazzani A.R. Genomic and nongenomic mechanisms of nitric oxide synthesis induction in endothelial cells by a fourth generation selective estrogen modulator. Endocrinology 2002, 143:2052-2061.
21. Fulton D., Gratton J.P., Sessa W.C. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough?. J. Pharmacol. Exp. Ther. 2001, 299:818-824.
22. Fulton D., Gratton P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., Sessa W.C. Regulation of endothelium derived nitric oxide production by protein kinase Akt. Nature 1999, 399:597-601.
23. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
24. Igarashi J., Thatte H.S., Prabhakar P., Golan D.E., Michel T. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:12583-12588.
25. Marletta M.A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994, 78:927-930.
26. Kuchan M.J., Frangos J.A. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. Am. J. Physiol. Cell Physiol. 1994, 266:C628-C636.
27. 2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ. Res. 1998, 82:686-695.
28. Sessa W.C. eNOS at a glance. J. Cell Sci. 2004, 17:2427-2429.
29. McCabe T.J., Fulton D., Roman L.J., Sessa W.C. Enhanced electron flux and reduced calmodulin dissociation may explain " calcium-independent" eNOS activation by phosphorylation. J. Biol. Chem. 2000, 275:6123-6128.
30. Mombouli J., Vanhoutte P. Kinins and endothelial control of vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 1995, 35:679-705.
31. Jagnandan D., Sessa W.C., Fulton D. Intracellular location regulates calcium-calmodulin-dependent activation of organelle-restricted eNOS. Am. J. Physiol. Cell Physiol. 2005, 289:1024-1033.
32. Sessa W.C., Pritchard K., Seyedi N., et al. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res. 1994, 74:349-353.
33. Prence E.M. Effects of calcium on phosphatidylserine- and saposin C-stimulated glucosylceramide beta-glucosidase activity. Biochem. J. 1995, 310:571-575.
34. Gattullo D., Pagliaro P., Marsh N.A., Losano G. New insights into nitric oxide and coronary circulation. Life Sci. 1999, 65:2167-2174.
35. Mülsch A., Bassenge E., Busse R. Nitric oxide synthesis in endothelial cytosol: evidence for a calcium-dependent and a calcium-independent mechanism. Naunyn Schmiedeberg's Arch. Pharmacol. 1989, 340:767-770.
36. Ayajiki K., Kindermann M., Hecker M., Fleming I., Busse R. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ. Res. 1996, 78:750-758.
37. Fleming I., Bauersachs J., Busse R. Calcium-dependent and independent activation of the endothelial NO synthase. J. Vasc. Res. 1997, 34:165-174.
38. Michel T. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:6252-6256.
39. Corson M.A., James N.L., Latta S.E., Nerem R.M., Berk B.C., Harrison D.G. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res. 1996, 79:984-991.
40. Garcia-Cardena G., Fan R., Stern D.F., Liu J., Sessa W.C. Endothelial nitric oxide is regulated by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem. 1996, 271:27237-27240.
41. Gallis B., Corthals G.L., Goodlett D.R., Ueba H., Kim F., Presnell S.R., Figeys D., Harrison D.G., Berk B.C., Aebersold R., Corson M.A. Identification of flow dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J. Biol. Chem. 1999, 274:30101-30108.
42. Butt E., M.BernhardtSmolenski A., Kotsonis P., Frohlich L.G., Sickmann A., Meyer H.E., Lohmann S.M., Schmidt H.H. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J. Biol. Chem. 2000, 275:5179-5187.
43. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., Power D.A., Ortiz de Montellano P.R., Kemp B.E. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999, 443:285-289.
44. 2+/calmodulin-dependent endothelial nitric oxide synthase activity. Circ. Res. 2001, 88:68-75.
45. Michell B.J., Griffiths J.E., Mitchelhill K.I., Rodriguez-Crespo I., Tiganis T., Bozinovski S., de Montellano P.R., Kemp B.E., Pearson R.B. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 1999, 9:845-848.
46. Michell B.J., Chen Z., Tiganis T., Stapleton D., Katsis F., Power D.A., Sim A.T., Kemp B.E. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem. 2001, 276:17625-17628.
47. Harris M.B., Ju H., Venema V.J., Liang H., Zou R., Michell B.J., Chen Z.P., Kemp B.E., Venema R.C. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J. Biol. Chem. 2001, 276:16587-16591.
48. Kou R., Greif D., Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J. Biol. Chem. 2002, 277:29669-29673.
49. Fulton D., Church J.E., Ruan L., Li C., Sood S.G., Kemp B.E., et al. Src kinase activates endothelial nitric oxide synthase by phosphorylating Tyr 83. J. Biol. Chem. 2005, 43:35943-35952.
50. Fulton D., Ruan L., Sood S.G., Li C., Zhang Q., Venema R.C. Agonist-stimulated endothelial nitric oxide synthase activation and vascular relaxation: role of eNOS phosphorylation at Tyr83. Circ. Res. 2008, 102:497-504.
51. Okuda M., Takahashi M., Suero J., Murry C.E., Traub O., Kawakatsu H., Berk B.C. Shear stress stimulation of p130(cas) tyrosine phosphorylation requires calcium-dependent c-Src activation. J. Biol. Chem. 1999, 274:26803-26809.
52. Tai L.K., Okuda M., Abe J., Yan C., Berk B.C. Fluid shear stress activates proline-rich tyrosine kinase via reactive oxygen species-dependent pathway. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1790-1796.
53. Fisslthaler B., Loot A.E., Mohamed A., Busse R., Fleming I. Inhibition of endothelial nitric oxide synthase activity by proline-rich tyrosine kinase 2 in response to fluid shear stress and insulin. Circ. Res. 2008, 102:1520-1528.
54. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin requiring enzyme. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:682-685.
55. Forstermann U., et al. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:1788-1792.
56. Durán W.N., Seyama A., Yoshimura K., González D.R., Jara P.I., Figueroa X.F., Boric M.P. Stimulation of NO production and of eNOS phosphorylation in the microcirculation in vivo. Microvasc. Res. 2000, 60:104-111.
57. Li Y., Zheng J., Bird I.M., Magness R.R. Mechanisms of shear stress-induced endothelial nitric-oxide synthase phosphorylation and expression in ovine fetoplacental artery endothelial cells. Biol. Reprod. 2004, 70:785-796.
58. Scotland R.S., Morales-Ruiz M., Chen Y., Yu J., Rudic R.D., Fulton D., Gratton J.P., Sessa W.C. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ. Res. 2002, 90:904-910.
59. Wang Y., Nagase S., Koyama A. Stimulatory effect of IGF-I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3-K signaling pathway. Nitric Oxide 2004, 10:25-35.
60. Bae S.W., Kim H.S., Cha Y.N., Park Y.S., Jo S.A., Jo I. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. Biochem. Biophys. Res. Commun. 2003, 306:981-987.
61. Michell B.J., Harris M.B., Chen Z.P., Ju H., et al. Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J. Biol. Chem. 2002, 277:42344-42351.
62. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 2003, 278:45021-45026.
63. Rocks O., Peyker A., Kahms M., Verveer P.J., Koerner C., Lumbierres M., Kuhlmann J., Waldmann H., Wittinghofer A., Bastiaens P.I. An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 2005, 307:1746-1752.
64. Sowa G., Liu J., Papapetropoulos A., Rex-Haffner M., Hughes T.E., Sessa W.C. Trafficking of endothelial nitric-oxide synthase in living cells: quantitative evidence supporting the role of palmitoylation as a kinetic trapping mechanism limiting membrane diffusion. J. Biol. Chem. 1999, 274:22524-22531.
65. Sakoda T., Hirata K., Kuroda R., Miki N., Suematsu M., Kawashima S., Yokoyama M. Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release of nitric oxide. Mol. Cell Biochem. 1995, 152:143-148.
66. Busconi L., Michel T. Endothelial nitric oxide synthase. N-terminal myristoylation determines subcellular localization. J. Biol. Chem. 1993, 268:8410-8413.
67. Liu I., Hughes T.E., Sessa W.C. The first 35 amino acids and fatty acylation sites determine the molecular targeting of endothelial nitric oxide synthase into the Golgi region of cells: a green fluorescent protein study. J. Cell Biol. 1997, 137:1525-1535.
68. Robinson L.J., Michel T. Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:11776-11780.
69. Robinson L.J., Busconi L., Michel T. Agonist-modulated palmitoylation of endothelial nitric oxide synthase. J. Biol. Chem. 1995, 270:995-998.
70. Parton R.G. Caveolae and caveolins. Curr. Opin. Cell Biol. 1996, 8:542-548.
71. Smart E.J., Graf G.A., McNiven M.A., Sessa W.C., Engelman J.A., Scherer P.E., Okamoto T., Lisanti M.P. Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell. Biol. 1999, 19:7289-7304.
72. Garcia-Cardena G., Oh P., Liu J., Schnitzer J.E., Sessa W.C. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:6448-6453.
73. Feron O., Belhassen L., Kobzik L., Smith T.W., Kelly R.A., Michel T. Endothelial nitric oxide synthase targeting to caveolae: specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J. Biol. Chem. 1996, 271:22810-22814.
74. Garcia-Cardena G., Martasek P., Masters B.S., Skidd P.M., Couet J., Li S., Lisanti M.P., Sessa W.C. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin: functional significance of the NOS caveolin binding domain in vivo. J. Biol. Chem. 1997, 272:25437-25440.
75. Bulotta S., Cerullo A., Barsacchi R., Palma Rotiroti C.D., Clementi E., Borgese N. Endothelial nitric oxide synthase is segregated from caveolin-1 and localizes to the leading edge of migrating cells. Exp. Cell Res. 2006, 312:877-889.
76. Maniatis N.A., Brovkovych V., Allen S.E., John T.A., Shajahan A.N., Tiruppathi C., Vogel S.M., Skidgel R.A., Malik A.B., Minshall R.D. Novel mechanism of endothelial nitric oxide synthase activation mediated by caveolae internalization in endothelial cells. Circ. Res. 2006, 99:870-877.
77. Heijnen H.F., Waaijenborg S., Crapo J.D., Bowler R.P., Akkerman J.W., Slot J.W. Colocalization of eNOS and the catalytic subunit of PKA in endothelial cell junctions: a clue for regulated NO production. J. Histochem. Cytochem. 2004, 52:1277-1285.
78. Sowa G., Pypaert M., Sessa W.C. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:14072-14077.
79. Jiang I., Cyr D., Babbitt R.W., Sessa W.C., Patterson C. Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the cochaperone/ubiquitin ligase CHIP. J. Biol. Chem. 2003, 278:49332-49341.
80. Nedvetsky P.I., Sessa W.C., Schmidt H.H. There's NO binding like NOS binding:protein-protein interactions in NO/cGMP signaling. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:16510-16512.
81. Zabel U., Kleinschnitz C., Oh P., Nedvetsky P., Smolenski A., Müller H., Kronich P., Kugler P., Walter U., Schnitzer J.E., Schmidt H.H. Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat. Cell Biol. 2002, 4:307-311.
82. Sessa W.C., Garcia-Cardena G., Liu J., Keh A., Pollock J.S., Bradley J., Thiru S., Braverman I.M., Desai K.M. The golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J. Biol. Chem. 1995, 270:17641-17644.
83. Shaul P.W., Smart E.J., Robinson L.J., German Z., Yuhanna I.S., Ying Y., Anderson R.G., Michel T. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem. 1996, 271:6518-6522.
84. Hecker I., Mulsch A., Bassenge E., Förstermann U., Busse R. Subcellular localization and characterization of nitric oxide synthase(s) in endothelial cells: physiological implications. Biochem. J. 1994, 299:247-252.
85. Rizzo V., McIntosh D.P., Oh P., Schnitzer J.E. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J. Biol. Chem. 1998, 273:34724-34729.
86. Feng Y., Venema V.J., Venema R.C., Tsai N., Caldwell R.B. VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem. Biophys. Res. Commun. 1999, 256:192-197.
87. Goetz R.M., Thatte H.S., Prabhakar P., Cho M.R., Michel T., Golan D.E. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:2788-2793.
88. 2+-calmodulin and caveolin. J. Biol. Chem. 1997, 272:15583-15586.
89. Prabhakar P., Thatte H.S., Goetz R.M., Cho M.R., Golan D.E., Michel T. Receptor-regulated translocation of endothelial nitric-oxide synthase. J. Biol. Chem. 1998, 273:27383-27388.
90. Venema V.J., Marrero M.B., Venema R.C. Bradykinin-stimulated protein tyrosine phosphorylation promotes endothelial nitric oxide synthase translocation to the cytoskeleton. Biochem. Biophys. Res. Commun. 1996, 226:703-710.
91. Wang Q., Patton W.F., Hechtman H.B., Shepro D. A novel anti-inflammatory peptide inhibits endothelial cell cytoskeletal rearrangement, nitric oxide synthase translocation, and paracellular permeability increases. J. Cell Physiol. 1997, 172:171-182.
92. Kai S., Toomre D. Lipid rafts and signal transduction. Nat. Rev. 2000, 1:31-43.
93. Sánchez F.A., Savalia N.B., Durán R.G., Lal B.K., Boric M.P., Durán W.N. Functional significance of differential eNOS translocation. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:1058-1064.
94. 2 prosurvival effects in cultured endothelial cells. FASEB J. 2006, 20:1501-1503.
95. Wann-Hansson C., Hallberg I.R., Risberg B., Lundell A., Klevsgard R. Health-related quality of life after revascularization for peripheral arterial occlusive disease: long-term follow-up. J. Adv. Nurs. 2005, 51:227-235.
96. Jialal I., Devaraj S., Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension 2004, 44:6-11.
97. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
98. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
99. Napp A., Brixius K., Pott C., Ziskoven C., Boelck B., Mehlhorn U., Schwinger R.H., Bloch W. Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium. J. Card. Fail. 2009, 15:57-67.
100. Tanaka S., Toh Y., Mori R., Komori K., Okadome K., Sugimachi K. Possible role of cytomegalovirus in the pathogenesis of inflammatory aortic diseases: a preliminary report. J. Vasc. Surg. 1992, 16:274-279.
101. Tanaka S., Komori K., Okadome K., Sugimachi K., Mori R. Detection of active cytomegalovirus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction. J. Vasc. Surg. 1994, 20:235-243.
102. Pampou S., Gnedoy S.N., Bystrevskaya V.B., Smirnov V.N., Chazov E.I., Melnick J.L., et al. Cytomegalovirus genome and the immediate-early antigen in cells of different layers of human aorta. Virchows Arch. 2000, 436:539-552.
103. Duffy S.J., Keaney J.F., Holbrook M., Gokce N., Swerdloff P.L., Frei B., Vita J.A. Acute and chronic tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001, 104:151-156.
104. Anter E., Thomas S.R., Schulz E., Shapira O.M., Vita J.A., Keaney J.F. Activation of endothelial nitric-oxide synthase by the p38 MAPK in response to black tea polyphenols. J. Biol. Chem. 2004, 279:46637-46643.
105. Hambrecht R., Adams V., Erbs S., Linke A., Krankel N., Shu Y., Baither Y., Gielen S., Thiele H., Gummert J.F., Mohr F.W., Schuler G. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation 2003, 107:3152-3158.
106. Ashley B., Billig J., Ambrecht L., Wolfert M., Looft-Wilson Robin Preservation of EDHF-dependent vasodilation and connexin expression in hyperhomocysteinemic mice. FASEB J. 2007, 21:759-763.
107. Jiang X., Yang F., Tan H., Liao D., Bryan R.M., Randhawa J.K., Rumbaut R.E., Durante W., Schafer A.I., Yang X., Wang H. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2515-2521.
108. Robin C., Looft-Wilson B.S., Ashley, et al. Chronic diet-induced hyperhomocysteinemia impairs eNOS regulation in mouse mesenteric arteries. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:59-66.
109. Signorello M.G., Segantin A., Passalacqua M., Leoncini G. Homocysteine decreases platelet NO level via protein kinase C activation. Nitric Oxide 2009, 20:104-113.
110. Scherrer-Crosbie I., Ullrich R., Bloch K.D., Nakajima H., Nasseri B., Aretz H.T., Lindsey M.L., Vancon A.C., Huang P.L., Lee R.T., Zapol W.M., Picard M.H. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001, 104:1286-1291.
111. Sartorio C.L., Fraccarollo D., Leutke M., Bauersachs J. The selective aldosterone receptor antagonist eplerenone improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Circulation 2005, 110(Suppl. II):262.
112. Fraccarollo D., Galuppo P., Hildemann S., Christ M., Ertl G., Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J. Am. Coll. Cardiol. 2003, 42:1666-1673.
113. Calvert J.W., Gundewar S., Jha S., Greer J.J.M., Bestermann W.H., Tian R., Lefer David J. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008, 57:696-705.
114. Iadecola C. Bright and dark sides of nitric oxide in ischaemic brain injury. Trends Neurosci. 1997, 20:132-139.
115. Samdani A.F., et al. Nitric oxide synthase in models of focal ischemia. Stroke 1997, 28:1283-1288.
116. Huang Z., et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-l-arginine. J. Cereb. Blood Flow Metab. 1996, 16:981-987.
117. Dalkara T., et al. Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia. Am. J. Physiol. 1994, 267:678-683.
118. Osuka K., Watanabe Y., Usuda N., Nakazawa A., Tokuda M., Yoshida M.J. Modification of endothelial no synthase through protein phosphorylation after forebrain cerebral ischemia/reperfusion. Stroke 2004, (35):2582.
119. Hashiguchi A., Yano S., Morioka M., Hamada J., Kochi M., Fukunaga K. Dephosphorylation of eNOS on Thr495 after transient forebrain ischemia in gerbil hippocampus. Brain Res. Mol. Brain Res. 2005, 133:317-319.
120. Atochin D.N., Wang A., Liu V.W., Critchlow J.D., Dantas A.P., Looft-Wilson R., Murata T., Salomone S., Shin H.K., Ayata C., Moskowitz M.A., Michel T., Sessa W.C., Huang P.L. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J. Clin. Invest. 2007, 117:1961-1967.
121. Izuishi K., Tsung A., Hossain M.A., Fujiwara M., Wakabayashi H., Masaki T. Ischemic preconditioning of the murine liver protects through the Akt kinase pathway. Hepatology 2006, 44:573-580.
122. Wang Y., Vodovotz Y., Kim P.K., Zamora R., Billiar T.R. Mechanisms of hepatoprotection by nitric oxide. Ann. N.Y. Acad. Sci. 2002, 962:415-422.
123. Taniai H., Hines I.N., Bharwani S., Maloney R.E., Nimura Y., Gao B., Flores S.C., McCord J.M., Grisham M.B., Aw T.Y. Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: role for NO and Kupffer cell-derived oxidants. Hepatology 2004, 39:1544-1552.
124. Roviezzo F., Cuzzocrea S., Di Lorenzo A., Brancaleone V., Mazzon E., Di Paola R., Bucci M., Cirino G. Protective role of PI3-kinase-Akt-eNOS signalling pathway in intestinal injury associated with splanchnic artery occlusion shock. Br. J. Pharmacol. 2007, 151:377-383.
125. Shi Y., Baker J.E., Zhang C., Tweddell J.S., Su J., Kirkwood A., Pritchard A. Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heat shock protein 90 association and serine phosphorylation. Circ. Res. 2002, 91:300-306.
126. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
127. Murata T., Sato K., Hori M., Ozaki H., Karaki H. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J. Biol. Chem. 2002, 277:44085-44092.
128. Coulet F., Nadaud S., Agrapart M., Soubrier F. Identification of hypoxia-response element in the human endothelial nitric oxide synthase gene promoter. J. Biol. Chem. 2003, 278:46230-46240.
129. Liu J., Gao Y., Negash S., Longo L.D., Raj J.U. Long-term effects of prenatal hypoxia on endothelium-dependent relaxation responses in pulmonary arteries of adult sheep. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:547-554.
130. Rother K.I. Diabetes treatment-bridging the divide. N. Engl. J. Med. 2007, 356:1499-1501.
131. Tierney L.M., McPhee S.J., Papadakis M.A. Current Medical Diagnosis & Treatment, International Edition 2002, Lange Medical Books, McGraw-Hill, New York, 1203-1215.
132. Laight D.W., Carrier M.J., Anggard E.E. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res. 2000, 47:457-464.
133. Tesfamariam B., Brown M.L., Deykin D., et al. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J. Clin. Invest. 1990, 85:929-932.
134. Bohlen H.G., Lash J.M. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am. J. Physiol. 1993, 265:219-225.
135. Meraji S., Jayakody L., Senaratne M.P., et al. Endothelium-dependent relaxation in aorta of BB rat. Diabetes 1987, 36:978-981.
136. Pieper G.M., Meier D.A., Hager S.R. Endothelial dysfunction in a model of hyperglycemia and hyperinsulinemia. Am. J. Physiol. 1995, 269:845-850.
137. Johnstone M.T., Creager S.J., Scales K.M., et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993, 88:2510-2516.
138. Williams S.B., Cusco J.A., Roddy M.A., et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 1996, 27:567-574.
139. Clarkson P., Celermajer D.S., Donald A.E., et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 1996, 28:573-579.
140. McVeigh G.E., Brennan G.M., Johnston G.D., et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992, 35:771-776.
141. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 2001, 108:1341-1348.
142. Okon E.B., Chung A.W., Rauniyar P., Padilla E., Tejerina T., McManus B.M., Luo H., van Breemen C. Compromised arterial function in human type 2 diabetic patients. Diabetes 2005, 54:2415-2423.
143. Okumura H., Nagaya N., Itoh T., Okano I., Hino J., Mori K., Tsukamoto Y., Ishibashi-Ueda H., Miwa S., Tambara K., Toyokuni S., Yutani C., Kangawa K. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 2004, 109:242-248.
144. Yang S., Lin L., Chen J.X., Lee C.R., Seubert J.M., Wang Y., Wang H., Chao Z.R., Tao D.D., Gong J.P., Lu Z.Y., Wang D.W., Zeldin D.C. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:142-151.
145. Kawasaki K., Smith R.S., Hsieh C.M., Sun J., Chao J., Liao J.K. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell Biol. 2003, 23:5726-5737.
146. Wang Y., Wei X., Xiao X., Hui R., Card J.W., Carey M.A., Wang D.W., Zeldin D.C. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J. Pharmacol. Exp. Ther. 2005, 314:522-532.
147. Shankar R.R., Wu Y., Shen H.Q., Zhu J.S., Baron A.D. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 2000, 49:684-687.
148. Duplain H., Burcelin R., Sartori C., Cook S., Egli M., Lepori M., Vollenweider P., Pedrazzini T., Nicod P., Thorens B., Scherrer U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001, 104:342-345.
149. Cook S., Hugli O., Egli M., Menard B., Thalmann S., Sartori C., Perrin C., Nicod P., Thorens B., Vollenweider P., Scherrer U., Burcelin R. Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet-induced insulin resistance and arterial hypertension. Diabetes 2004, 53:2067-2072.
150. Zeng G., Nystrom F.H., Ravichandran L.V., Cong L.N., Kirby M., Mostowski H., Quon M.J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000, 101:1539-1545.
151. 2+ but requires phosphorylation by Akt at Ser(1179). J. Biol. Chem. 2001, 276:30392-30398.
152. Musicki B., Kramer M.F., Becker R.E., Arthur Burnett L. Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc. Natl. Acad. Sci. U.S.A 2005, 102:11870-11875.
153. Elrod J.W., Duranski M.R., Langston W., Greer J.J., Tao L., Dugas T.R., Kevil C.G., Champion H.C., Lefer D.J. eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling. Circ. Res. 2006, 99:78-85.
154. Marks D.S., Vita J.A., Folts J.D., Keaney J.F.J., Welch G.N., Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J. Clin. Invest. 1995, 96:2630-2638.
155. Masters K.S., Lipke E.A., Rice E.E., Liel M.S., Myler H.A., Zygourakis C., Tulis D.A., West J.L. Nitric oxide-generating hydrogels inhibit neointima formation. J. Biomater. Sci. Polym. Ed. 2005, 16:659-672.
156. Kapadia M.R., Chow L.W., Tsihlis N.D., Ahanchi S.S., Eng J.W., Murar J., Martinez J., Popowich D.A., Jiang Q., Hrabie J.A., Saavedra J.E., Keefer L.K., Hulvat J.F., Stupp S.I., Kibbe M.R. Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia. J. Vasc. Surg. 2008, 47:173-182.
157. Li Y., Lee P.I. Controlled nitric oxide delivery platform based on s-nitrosothiol conjugated interpolymer complexes for diabetic wound healing. Mol. Pharm. 2010, 7:254-266.
158. Ahanchi S.S., Varu V.N., Tsihlis N.D., Martinez J., Pearce C.G., Kapadia M.R., Jiang Q., Saavedra J.E., Keefer L.K., Hrabie J.A., Kibbe M.R. Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:2388-2398.
159. Pearce C.G., Najjar S.F., Kapadia M.R., Murar J., Eng J., Lyle B., Aalami O.O., Jiang Q., Hrabie J.A., Saavedra J.E., Keefer L.K., Kibbe M.R. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic. Biol. Med. 2008, 44:73-81.
160. Nakagawa T., Sato W., Glushakova O., Heinig M., Clarke T., Campbell-Thompson M., Yuzawa Y., Atkinson M.A., Johnson R.J., Croker B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol 2007, 18:539-550.
161. Molnar J., Yu S., Mzhavia N., Pau C., Chereshnev I., Dansky H.M. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ. Res. 2005, 96:1178-1184.
162. Pennathur S., Heinecke J.W. Oxidative stress and endothelial dysfunction in vascular disease. Curr. Diab. Rep. 2007, 7:257-264.
163. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., Skatchkov M., Thaiss F., Stahl R.A., Warnholtz A., Meinertz T., Griendling K., Harrison D.G., Forstermann U., Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 2001, 88:14-22.
164. Chalupsky K., Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9056-9061.
165. Alp N.J., Mussa S., Khoo J., Cai S., Guzik T., Jefferson A., Goh N., Rockett K.A., Channon K.M. Tetrahydrobiopterin-dependent preservation of nitric oxidemediated endothelial function in diabetes by targeted transgenic GTPcyclohydrolase I overexpression. J. Clin. Invest. 2003, 112:725-735.
166. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., Tarpey M., Fukai T., Harrison D.G. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282-1288.
167. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209.
168. Munzel T., Daiber A., Ullrich V., Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1551-1557.
169. Harris M.B., Ju H., Venema V.J., Liang H., Zou R., Michell B.J., et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J. Biol. Chem. 2001, 276:16587-16591.
170. Chen C.A., Druhan L.J., Varadharaj S., Chen Y.R., Zweier J.L. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. J. Biol. Chem. 2008, 283:27038-27047.
171. O'Hara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 1993, 91:2546-2551.
172. Peterson T.E., Poppa V., Ueba H., Wu A., Yan C., Berk B.C. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ. Res. 1999, 85:29-37.
173. Landmesser U., Cai H., Dikalov S., McCann L., Hwang J., et al. Role of p47 (phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511-515.
174. Thomas S.R., Chen K., Keaney J.F. Hydrogen peroxide activates en-dothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3- kinase-dependent signaling pathway. J. Biol. Chem. 2002, 277:6017-6024.
175. Zhang H., Zhang J., Ungvari Z., Zhang C. Resveratrol improves endothelial function: role of TNF {alpha} and vascular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1164-1171.
176. Insull W. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am. J. Med. 2009, 122:3-14.
177. Liapis C.D., Avgerinos E.D., Kadoglou N.P., Kakisis J.D. What a vascular surgeon should know and do about atherosclerotic risk factors. J. Vasc. Surg. 2009, 49:1348-1354.
178. Safar M.E., Jankowski P. Central blood pressure and hypertension: role in cardiovascular risk assessment. Clin. Sci. 2009, 116:273-282.
179. Werner C.M., Böhm M. The therapeutic role of RAS blockade in chronic heart failure. Ther. Adv. Cardiovasc. Dis. 2008, 2:167-177.
180. Gaddam K.K., Verma A., Thompson M., Amin R., Ventura H. Hypertension and cardiac failure in its various forms. Med. Clin. North Am. 2009, 93:665-680.
181. Agabiti-Rosei E. From macro- to microcirculation: benefits in hypertension and diabetes. J. Hypertens. 2008, 26:15-21.
182. Murphy B.P., Stanton T., Dunn F.G. Hypertension and myocardial ischemia. Med. Clin. North Am. 2009, 93:681-695.
183. Tylicki L., Rutkowski B. Hypertensive nephropathy: pathogenesis, diagnosis and treatment. Pol. Merkuriusz. Lek. 2003, 14:168-173.
184. Truong L.D., Shen S.S., Park M.H., Krishnan B. Diagnosing nonneoplastic lesions in nephrectomy specimens. Archiv. Pathol. Lab Med. 2009, 133:189-200.
185. Tracy R.E., White S. A method for quantifying adrenocortical nodular hyperplasia at autopsy: some use of the method in illuminating hypertension and atherosclerosis. Ann. Diagn. Pathol. 2002, 6:20-29.
186. Singer D.R., Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?. Eur. J. Vasc. Endovasc. Surg. 2008, 35:701-708.
187. Aronow W.S. Hypertension and the older diabetic. Clin. Geriatr. Med. 2008, 24:489-501.
188. Gardner A.W., Afaq A. Management of lower extremity peripheral arterial disease. J. Cardiopulm. Rehab. Prev. 2008, 28(6):349-357.
189. Cahill P.A., Foster C., Redmond E.M., Gingalewski C., Wu Y., Sitzmann J.V. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology 1995, 22:598-606.
190. Martin P.Y., Xu D.L., Niederberger M., Weigert A., Tsai P., St John J., Gines P., Schrier R.W. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am. J. Physiol. Renal Fluid Electrolyte Physiol. 1996, 270:494-499.
191. Niederberger M., Gines P., Martin P.Y., Tsai P., Morris K., McMurtry I., Schrier R.W. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 1996, 24:947-951.
192. Niederberger M., Martin P.Y., Gines P., Morris K., Tsai P., Xu D.L., McMurtry I., Schrier R.W. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995, 109:1624-1630.
193. Iwakiri Y., Tsai M., Timothy J., McCabe T.J., Gratton J.P., Fulton D., Groszmann J.R., Sessa W.C. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:2084-2090.
194. Shah V. Molecular mechanisms in the pathogenesis of cirrhotic portal hypertension: focus on nitric oxide. J. Gastroenterol. Hepatol. 2004, 19:145-149.
195. Bivalacqua T.J., Usta F.Mustafa, Champion C.H., Kadowitz J.P., Hellstrom J.Wayne G. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J. Androl. 2003, 24.
196. Musicki B., Burnett A.l. eNOS function and dysfunction in the penis. Exp. Biol. Med. 2006, 231:154-165.
197. Hidetaka J., Masato E., Kano M.R., Ogawa S., Iijima K., Akishita M., Ouchi Y. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1634.
198. Minamino T., Miyauci H., Yoshida T., Ishida Y., Yoshida H., Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002, 105:1541-1544.
199. Burrig K.F. The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler. Thromb. 1991, 11:1678-1689.
200. Hayashi T., Matsui-Hirai H., Miyazaki-Akita A., Fukatsu A., Funami J., Ding Q.F., Kamalanathan S., Hattori Y., Ignarro L.J., Iguchi A. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17018-17023.
201. Vasa M., Breitschopf K., Zeiher A.M., Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ. Res. 2000, 87:540-542.
202. Kambayashi J., Liu Y., Sun B., Shakur Y., Yoshitake M., Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr. Pharm. Des. 2003, 9:2289-2302.
203. Hayashi T., Yano K., Matsui-Hirai H., Yokoo H., Hattori Y., Iguchi A. Nitric oxide and endothelial cellular senescence. Pharmacol. Ther. 2008, 120:333-339.
204. Hashimoto A., Miyakoda G., Hirose Y., Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006, 189:350-357.
205. Braunstein M., Rose A.B., Holmes S.G., Allis C.D., Broach J.R. Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. Genes Dev. 1993, 7:592-604.
206. Vaziri H., Dessain S.K., Eaton N.E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
207. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002, 21:2383-2396.
208. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429:771-776.
209. Nisoli E., Tonello C., Cardile A., Cozzi V., Bracale R., Tedesco L., Falcone S., Valerio A., Cantoni O., Clementi E., Moncada S., Carruba M.O. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005, 310:314-317.
210. Potente M., Dimmeler S. NO targets SIRT1: a novel signaling network in endothelial senescence. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1577-1579.
211. Korkmaz Y. The basal phosphorylation sites of endothelial nitric oxide synthase at serine (Ser)1177, Ser116, and threonine (Thr)495 in rat molar epithelial rests of malassez. J. Periodontol. 2005, 76:1513-1519.
212. Gentile M.T., Vecchione C., Maffei A., Aretini A., Marino G., Poulet R., Capobianco L., Selvetella G., Lembo G. Mechanisms of soluble β-amyloid impairment of endothelial function. J. Biol. Chem. 2004, 279:48135-48142.
213. Stamler J.S., Jia L., Eu J.P., McMahon T.J., Demchenko I.T., Bonaventura J., Gernert K., Piantadosi C.A. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 1997, 276:2034-2037.
214. Kleinbongard J., Schulz R., Rassaf T., et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006, 107:2943-2951.
215. Anuk T., Assayag E.B., Rotstein R., Fusman R., Zeltser D., Berliner S., Avitzour D., Shapira I., Arber N., Bornstein N.M. Prognostic implications of admission inflammatory profile in acute ischemic neurological events. Acta Neurol. Scand. 2002, 106:196-199.
216. Muda P., Kampus P., Zilmer M., Zilmer K., Kairane C., Ristimäe T., Fischer K., Teesalu R. Homocysteine and red blood cell glutathione as indices for middle-aged untreated essential hypertension patients. J. Hypertens. 2003, 21:2329-2333.
217. Mihov D., Vogel J., Gassmann M., Bogdanova A. Erythropoietin activates nitric oxide synthase in murine erythrocytes. Am. J. Physiol. Cell. Physiol. 2009, 297:378-388.
218. Ozüyaman B., Grau M., Kelm M., Merx M.W., Kleinbongard P. RBC NOS: regulatory mechanisms and therapeutic aspects. Trends Mol. Med. 2008, 14:314-322.
219. Suhr F., Porten S., Hertrich T., Brixius K., Schmidt A., Platen P., Bloch W. Intensive exercise induces changes of endothelial nitric oxide synthase pattern in human erythrocytes. Nitric Oxide 2009, 20:95-103.
220. Baskurt O.K., Meiselman H.J. RBC aggregation: more important than RBC adhesion to endothelial cells as a determinant of in vivo blood flow in health and disease. Microcirculation 2008, 15:585-590.
221. Berliner S., Rogowski O., Aharonov S., Mardi T., Tolshinsky T., Rozenblat M., Justo D., Deutsch V., Serov J., Shapira I., Zeltzer D. Erythrocyte adhesiveness/aggregation: a novel biomarker for the detection of low-grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular disease. Am. Heart J. 2005, 149:260-267.
222. Ludolph B., Bloch W., Kelm M., Schulz R., Kleinbongard P. Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity. Vasc. Health Risk Manag. 2007, 3:1069-1073.
223. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006, 6:521-534.
224. Hess D.T., et al. Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol. 2005, 6:150-166.
225. Lander H.M., et al. Redox regulation of cell signalling. Nature 1996, 380-381.
226. Hamilton M., Wolfman A. Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo. Oncogene 1998, 16:1417-1428.
227. Huang D.C., Marshall C.J., Hancock J.F. Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. Mol. Cell. Biol. 1993, 13:2420-2431.
228. Lim K.H., et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr. Biol. 2006, 16:2385-2394.
229. Santhanam A.V., Smith L.A., Akiyama M., Rosales A.G., Bailey K.R., Katusic Z.S. Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 2005, 36:2731-2737.
230. Leung F.P., Yung L.M., Leung H.S., Au C.L., Yao X., Vanhoutte P.M., Laher I., Huang Y. Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilatation in vitro. Br. J. Pharmacol. 2007, 152:223-229.
231. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 2003, 93:767-775.
232. Sawada N., Itoh H., Ueyama K., Yamashita J., Doi K., Chun T.H., Inoue M., Masatsugu K., Saito T., Fukunaga Y., Sakaguchi S., Arai H., Ohno N., Komeda M., Nakao K. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000, 101:2030-2033.
233. Shimokawa H., Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1767-1775.
234. Ming X.F., Viswambharan H., Barandier C., Ruffieux J., Kaibuchi K., Rusconi S., Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. 2002, 22:8467-8477.
235. Wolfrum S., Dendorfer A., Rikitake Y., Stalker T.J., Gong Y., Scalia R., Dominiak P., Liao J.K. Inhibition of Rho-kinase leads to rapid activation of phosphatidyl inositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1842-1847.
236. Mallat Z., Gojova A., Sauzeau V., Brun V., Silvestre J.S., Esposito B., Merval R., Groux H., Loirand G., Tedgui A. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ. Res. 2003, 93:884-888.
237. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol. 2002, 39:319-327.